Tag Archives: newsletter

Hot Investor Mandate 4: Germany-Based CVC with a Global Presence Invests in Innovative Medical Technologies Globally, Including Imaging & PoC and In Vitro Diagnostics

7 Jun

A corporate venture firm is headquartered in Munich, Germany, with additional offices worldwide. The fund invests in medical technology companies that are strategically relevant to the corporate’s interests. Investments in equity rounds range from $1-5 million and are made worldwide.

The firm’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the firm focuses on products used in a hospital setting. The firm also invests in digital health solutions that add value to imaging and diagnostics, such as data-as-a-service products. The firm is potentially interested in medical robotics. The firm will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: USA Venture Fund Invests in Therapeutics and Digital Health, With Strong Interests in Small Molecule Therapies in Inflammation, Infectious, Autoimmune Diseases

31 May

A USA-based venture capital fund is currently making investments out of a $150-million-dollar fund. The firm is looking to make 15 additional investments with allocations generally in the $1-3 million range. The firm is looking to make equity investments and is open to investing in companies globally.

The firm is interested in therapeutic companies developing small molecules for inflammation, infectious and autoimmune disease and stays away from biologics, cell and gene therapy. The firm is also interested in digital health and mobile health services, AI in healthcare, B2B2C medical devices. The firm is looking for companies with some level of proof-of-concept data either in vivo or in vitro up until Phase II of clinical trials. As for digital health, the firm is looking for scalable SAAS models, novel types of healthcare delivery, point-of-care diagnostics and patient’s self-management tools.

The firm is willing to work with incomplete management teams, often working with IP that has just recently spun out of a university. The firm is willing and able to act as a lead or co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Boston-Based VC Firm Makes Pre-Seed/Seed Investments in Data-Driven Technologies Including AI, Drug Discovery, and Computational Biotech

31 May

A venture firm headquartered in Boston, MA focus on pre-seed and seed stage investments, typically with an initially investment of $500K to $1M as part of the company’s first institutional funding. The firm prefers companies located in the USA and Canada. The firm will make 5-10 new investments over the next 12 months.

The firm partners with entrepreneurs solving real-world problems with data and machine learning, focusing on applications of frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Past investments include biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, and related areas.

The firm desires experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Strong technical teams who have a deep understanding of their markets is desired, though the firm is comfortable partnering with very early-stage (pre-product) companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: China-Based Investment Institution Invests in Early to Growth Stage Biotech Companies with Large Market Potential in China

31 May

A professional investment institution that is based in Shanghai invests in early and growth stage companies in the field of biomedicine through its fund management company. The firm currently manages a $100 million fund. Typical equity investments range from $5 to 20 million in Angel to Series B rounds. The firm is currently seeking opportunities from China, the US and Canada.

The firm’s key areas of focus include medicine, medical devices, diagnostics, biotechnology and healthcare services. The firm is seeking products that have large market potential in China and have achieved prototype and clinical proof-of-concept. The firm is agnostic when it comes to indication areas.

The firm is looking for competent management teams with validated assets. The firm can assist with finding registration and distribution partners in China and may request regional rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Japanese CVC with USA Offices Invests in Novel Pharmaceutical, Medical Device, and Digital Health Technologies

24 May

A corporate venture arm of a diversified business based in Tokyo is focused on investing in various sectors, including healthcare. The team is based in offices in both the West and East Coast. The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Healthcare Subsidiary of Large European Company Seeks Global Opportunities of All Stages that Address Chronic Medical Conditions

24 May

A wholly-owned subsidiary of a large conglomerate based in Western Europe is engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and our partners in healthcare. The firm invests in life science assets at various stages of development through collaboration, in-licensing, or M&A. The company’s allocations are varied in both size and structure, and the company is open to partnerships globally.

The firm has a strong foundation of enteral and oral nutrition products in Aging Medical Care, Critical Care & Surgery, and Pediatric Medical Care (including inborn errors of metabolism) and endeavors to develop nutritional solutions to address chronic medical conditions in the area of gut health, metabolic Health, healthy aging, and allergy. For partnering, the company currently focuses on product opportunities and technologies (i.e. microbiome) that address the same, including our acute care interests, and that also elevate the role of nutrition or leverage natural approaches to prevent and treat conditions that impact consumers and patients alike.

The firm is seeking competent teams with science-based nutritional solutions to deliver improved personalized health care for people with medical conditions. Collaborators can benefit from working with the the firm’s vast R&D network, including a dedicated R&D Center located in Bridgewater, New Jersey.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Firm Partnered with a Family Office Seeking to Provide Seed Capital to USA-Based Therapeutics Opportunities

17 May

A Chicago-based life sciences investment fund is focused on accelerating the growth of early-stage biotechnology and pharmaceutical companies. Partnered with a family investment office, the firm seeks to make 10 seed round investments within the next year. The firm will invest in companies based in the U.S.

The firm is seeking investments in biotech/therapeutics companies and is not interested in medical device or digital health technologies. The firm is interested in companies with assets or platform technologies in preclinical or early clinical development and is indication agnostic.

The firm does not have any company management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: